Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Samsung/Merck Closer To US Biosimilars Market; Infliximab App Accepted

Executive Summary

If the FDA approves Samsung Bioepis' and Merck's biosimilar version of Remicade, known as SB2, which is now under review at the agency, the firms not only will have Janssen Biotech Inc. to contend with, but Celltrion and Pfizer Inc., which won approval last month of the first infliximab biosimilar in the US.


Related Content

Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Court Probes Rationale Of Biosimilars' 180-Day Notice
Sandoz Dares SCOTUS To Unravel Biosimilars Law's Riddles
Court rules biosimilar 'patent dance' optional, but delays Zarxio
Federal Circuit dances with biosimilar law's complexity in Zarxio fight
Janssen seeks to block Celltrion's infliximab biosimilar
Novartis/Sandoz make history with 1st US biosimilar Zarxio


Related Companies